EMA Authorised: Imjudo (tremelimumab) — AstraZeneca AB

View source ↗

Summary

EMA has authorised Imjudo (tremelimumab) from AstraZeneca AB for hepatocellular carcinoma and non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• IMJUDO (TREMELIMUMAB)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Hepatocellular;Carcinoma, Non-Small-Cell Lung. MAH: AstraZeneca AB. Decision date: 04/08/2025